JCI table of contents: March 20, 2008(acy in rodent models of autoimmune disea...),Health

Date:3/20/2008

acy in rodent models of autoimmune diseases. New data generated by Holger M. Reichardt and colleagues at the University of Goettingen Medical School, Germany, has now provided more insight into the effects of drugs similar to TGN1412 in rats, but as with the preclinical trials no evidence of the devastating consequences in humans were observed. As pointed out in an accompanying commentary by William St. Clair, at Duke University Medical Center, Durham, these data serve to highlight the different responses of rodents and humans to drugs like TGN1412, and raise questions about how best to design preclinical studies that can better predict the risks of novel immunotherapeutics in humans.?

TITLE: A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats

AUTHOR CONTACT:
Holger M. Reichardt
University of Goettingen Medical School, Goettingen, Germany.
Phone: 49-551-393365; Fax: 49-551-395843; E-mail: hreichardt@med.uni-goettingen.de.

View the PDF of this article at: https://www.the-jci.org/article.php?id=32698

ACCOMPANYING COMMENTARY

TITLE: The calm after the cytokine storm: lessons from the TGN1412 trial

AUTHOR CONTACT:
E. William St. Clair
Duke University Medical Center, Durham, North Carolina, USA.
Phone: (919) 684-4499; Fax: (919) 684-8358; E-mail: stcla003@mc.duke.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=35382

---

ONCOLOGY: The protein TM4SF5 lets tumor cells grow out of control

A characteristic of tumor cells is that they grow in an uncontrolled manner. One reason for this is that although normal cells stop growing when they contact one another (a process
'/>"/>

Contact: Karen Honey press_releases@the-jci.org 215-573-1850 Journal of Clinical Investigation Source:Eurekalert

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Blue Cross and Blue Shield of Illinois Announces 2007 Charitable Donations
2. GSK Charitable Support Valued at $564 Million in 2007
3. JCI online early table of contents: March 13, 2008
4. Implantable medical devices may expose patients to security, privacy risks; solutions suggested
5. Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets
6. Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets
7. V8 V-Fusion(R) Takes an Exotic, Tasty Twist on Vegetable Juice
8. JCI online early table of contents: March 3, 2008
9. AXA Equitable Meets the Needs of Two People under One Life Insurance Policy
10. Nanomedicine system engineered to enhance therapeutic effects of injectable drugs
11. Nurses Convince Hospital to Return to Bargaining Table